ADB is committed to achieving a prosperous, inclusive, resilient, and sustainable Asia and the Pacific, while sustaining its efforts to eradicate extreme poverty.
Established in 1966, it is owned by 68 members—49 from the region.
ORGANIZATION
ACCOUNTABILITY
ADB supports projects in developing member countries that create economic and development impact, delivered through both public and private sector operations, advisory services, and knowledge support.
Azerbaijan and ADB
The ADB–Azerbaijan partnership supports the private sector, realizes green energy initiatives, raises public sector efficiency, improves infrastructure, and strengthens human capital.
ADB COVID-19 Response: Azerbaijan
ADB's COVID-19 Response is a $20 billion package to support its developing member countries in countering the severe macroeconomic and health impacts caused by COVID-19, including $2.5 billion in concessional and grant resources, as well as $2 billion earmarked for the private sector (nonsovereign).
The Asia Pacific Vaccine Access Facility (APVAX) is ADB's $9 billion vaccine initiative offering rapid and equitable support to its developing member countries as they procure and deliver effective and safe COVID-19 vaccines.
Committed Amount is the financing approved by ADB's Board of Directors or Management for which the legal agreement has been signed by the borrower, recipient, or the investee company and ADB.
*The number of projects excludes short-term finance transactions under the Trade Finance, Supply Chain Finance, and Microfinance Programs.
ADB COVID-19 Projects in Azerbaijan
COVID-19 Blogs and Multimedia: Azerbaijan
Blogs and Articles
COVID-19 Publications and Documents
Metropolitan Area Delineation and Resilience Under a Public Health Crisis: Evidence from the Philippines
This paper delineates and examines the dynamics of metropolitan areas in the Philippines during the COVID-19 pandemic.
Strengthening the Regulatory Ecosystem for Vaccines in Bangladesh: Landscape and Policy Recommendations
This brief analyzes how Bangladesh can strengthen its regulatory ecosystem to bolster vaccine and pharmaceutical manufacturing, improve public health outcomes, and better prepare for future health emergencies.
Creating an Enabling Environment for Vaccine Manufacturing in Bangladesh: Landscape and Policy Recommendations
This brief analyzes Bangladesh’s thriving vaccine manufacturing industry and suggests how steps to strengthen intellectual property protection and build a skilled workforce can help it attract the investment it needs to scale up.
What Has COVID-19 Taught Us About Asia’s Health Emergency Preparedness and Response?
This publication highlights the importance of adequately investing in healthcare infrastructure and preparedness and of applying flexibility, innovation, and collaboration in preparing for future health emergencies.